Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly’s Mirikizumab Hits All Marks In First Phase III Study For UC

Mar 16 2021

• By Joseph Haas

Lilly gets positive Phase III data for its anti-IL-23 candidate in ulcerative colitis

Related Content

Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis

Jul 17 2020

Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab

Jan 10 2020

Related Companies

Eli Lilly and Company

AbbVie Inc.

Novartis AG

Johnson & Johnson

Sun Pharmaceutical Industries Ltd.

Dermira Inc.

Additional Topics

Clinical Trials Drug Approval Standards Research & Development Gastrointestinal BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.